TATX 01
Alternative Names: TATX-01Latest Information Update: 09 Feb 2023
At a glance
- Originator Talem Therapeutics
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 08 Feb 2023 Discontinued for Unspecified in USA (unspecified route) (Talem Therapeutics pipeline, February 2023)
- 02 Nov 2022 TATX 01 is available for licensing as of 02 Nov 2022. https://talemtherapeutics.com/ (Talem Therapeutics website, November 2022)
- 02 Nov 2022 Early research in Unspecified in USA (unspecified route) (Talem Therapeutics website, November 2022)